在创新药行业经历周期调整的背景下,百济神州交出了一份令市场振奋的成绩单。2024年,公司营业总收入同比增长56.2%至272.14亿元,产品收入同比大幅增长74.1%,核心产品泽布替尼全球销售额突破188.59亿元,同比增长106.4%。公司正在以“中国创新”重构全球BTK抑制剂市场版图。百济神州的国际化战略是其最显著的核心竞争力之一。公司在中、美、欧三大市场同步推进产品商业化,2024年海外收入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.